Trevi Therapeutics 경영진
경영진 기준 점검 3/4
Trevi Therapeutics CEO는 Jennifer Good, Mar2011 에 임명되었습니다 의 임기는 15.25 년입니다. 총 연간 보상은 $3.94M, 15.8% 급여 및 84.2% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $2.84M 가치에 해당하는 회사 주식의 0.15% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.2 년과 9.1 년입니다.
핵심 정보
Jennifer Good
최고경영자
US$3.9m
총 보수
| CEO 급여 비율 | 15.78% |
| CEO 재임 기간 | 15.3yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | 5.2yrs |
| 이사회 평균 재임 기간 | 9.1yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Apr 17
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk
Summary Trevi Therapeutics is transitioning to a late-stage biotech, prioritizing Haduvio for IPF-related chronic cough as its lead indication. TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chronic cough, with quantifiable endpoints and safety focus, are the pivotal near-term catalysts for TRVI. Despite a premium valuation (P/B 10.2x–16.3x), TRVI's upside relies on successful late-stage execution; I recommend holding until Phase 3 data. Read the full article on Seeking Alpha
새로운 내러티브 • Mar 19
Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?분석 기사 • Apr 02
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Sep 19
Trevi adds 19% on full data set from mid-stage cough study
Clinical-stage biopharma, Trevi Therapeutics, Inc. (NASDAQ:TRVI) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CANAL study was designed to compare Haduvio, an oral extended-release formulation of pain therapy nalbuphine, against placebo in terms of the mean daytime cough frequency at Day 22 as the primary endpoint, as measured by an objective cough monitor. The full set of subjects (N=38) reached the primary endpoint with statistical significance indicating a 52.5% change in daytime cough frequency for Haduvio compared to placebo (p<0.0001). The reduction of cough frequency stood at ~76.1% and 25.3% in Haduvio and placebo arms, respectively. The safety profile was in line with data from previous studies for the treatment, and two adverse events were found to be unrelated to the experimental therapy. TRVI expects to start the next trial for this indication in H1 2023. A previous readout from 26 patients in the CANAL trial indicated a 52% placebo-adjusted reduction in daytime cough events for Haduvio.Seeking Alpha • Sep 11
Trevi Therapeutics: Moving Forward
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fibrosis. An investment analysis follows in the paragraphs below. "It's not unpatriotic to denounce an injustice committed on our behalf, perhaps it's the most patriotic thing we can do."― E.A. Bucchianeri Today, we take our first look at Trevi Therapeutics Inc. (TRVI). The small biopharma firm came public just over three years ago and is deep in Busted IPO territory even with a nice rebound in the shares so far in 2022. What lies ahead for Trevi Therapeutics? An analysis follows below. Seeking Alpha Company Overview Trevi Therapeutics is a clinical-stage biopharmaceutical company based out of New Haven, CT. The company focuses on the development of medicines to treat serious neurologically mediated conditions. Its primary asset in development is Haduvio which is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Haduvio has a dual mechanism of action by acting as both an antagonist (blocker) to the body's mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. March Company Presentation This candidate is currently being evaluating for the treatment of prurigo nodularis or PN and chronic cough in adults with idiopathic pulmonary fibrosis or IPF. Chronic cough represents a significant unmet need for IPF patients, as the majority of these patients report this cough as one of their most bothersome aspects of their disease. March Company Presentation Haduvio or Nalbuphine Extended Release [ER] has also been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. In 2011, Endo Pharmaceuticals partnered with Trevi to develop and market compounds incorporating nalbuphine hydrochloride. The stock currently trades just over three bucks a share and sports an approximate market capitalization of $140 million. Pipeline Developments Company Website The stock got a bump in late June 29th when the company disclosed that Haduvio had met key goals in a Phase 2b/3 'PRISM' study for patients with prurigo nodularis. 25% met the primary efficacy endpoint, a clinical measure called 4-point reduction in the Worst Itch - Numerical Rating Scale compared to just 14% of the placebo group. March Company Presentation Patients are currently completing the one-year open-label extension study, which should be over in January. The company is in the process of having an end of Phase 2 meeting with the FDA to discuss the data, next steps and the design for a registrational study that could lead to approval dependent on results. The company would like to do a six-month study with three treatment groups. March Company Presentation Four months before, interim data from a Phase 2 trial evaluating Haduvio to treat IPF suffering from chronic cough found a 52% placebo-adjusted reduction in daytime cough events and the compound was well tolerated. Full results should be out by the end of this quarter. A meeting with the FDA should happen to soon to move this effort to the next stage of development. The company believes this will begin in the first half of 2023. Haduvio could have other potential indications in this category (see above) for other indications. March Company Presentation Analyst Commentary & Balance Sheet Aegis Capital, Oppenheimer and Needham have all reiterated Buy ratings on TRVI over the past four months. All have identical $10 price targets on the stock.분석 기사 • Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$46m |
| Dec 31 2025 | US$4m | US$622k | -US$43m |
| Sep 30 2025 | n/a | n/a | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$47m |
| Mar 31 2025 | n/a | n/a | -US$47m |
| Dec 31 2024 | US$3m | US$608k | -US$48m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$597k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$898k | US$523k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$2m | US$506k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$1m | US$478k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$30m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$3m | US$435k | -US$27m |
보상 대 시장: Jennifer의 총 보수(USD3.94M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.30M) 수준입니다.
보상과 수익: Jennifer의 보상은 회사가 적자임에도 증가했습니다.
CEO
Jennifer Good (61 yo)
15.3yrs
재임 기간
US$3,944,892
보수
Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011 and had been its Interim Principal Financial Officer since Au...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$3.94m | 0.15% $ 2.8m | |
| Chief Development Officer | 1.8yrs | US$1.64m | 0% $ 0 | |
| Chief Commercial Officer | 5.8yrs | US$1.36m | 0.057% $ 1.1m | |
| Co-Founder & Chief Scientific Officer | 15.3yrs | US$977.13k | 0.16% $ 3.0m | |
| Chief Financial Officer & Principal Financial Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Controller & Chief Accounting Officer | 5.2yrs | 데이터 없음 | 0.018% $ 347.9k | |
| Communications Manager | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP of Global Regulatory Affairs | 1.4yrs | 데이터 없음 | 데이터 없음 |
5.2yrs
평균 재임 기간
65yo
평균 나이
경험이 풍부한 관리: TRVI의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.2 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 15.3yrs | US$3.94m | 0.15% $ 2.8m | |
| Independent Director | 7.7yrs | US$283.43k | 0.018% $ 346.3k | |
| Independent Director | 6yrs | US$275.93k | 0% $ 0 | |
| Independent Director | 8.9yrs | US$265.93k | 0% $ 0 | |
| Independent Chairman of the Board | 8.9yrs | US$293.43k | 0.25% $ 4.7m | |
| Independent Director | 9.3yrs | US$283.43k | 0.0045% $ 84.6k | |
| Member of Clinical Advisory Board | 13.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board | 13.3yrs | 데이터 없음 | 데이터 없음 |
9.1yrs
평균 재임 기간
64yo
평균 나이
경험이 풍부한 이사회: TRVI의 이사회는 경험이 있음으로 간주됩니다(평균 재임 9.1 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/08 15:21 |
| 종가 | 2026/06/08 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Trevi Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |